CO6460741A2 - STABLE FORMS OF N- (2,6-DIMETIL-4-MORFOLIN-4-IL-FENIL) -3,3-DIMETIL-BUTIRAMIDA - Google Patents

STABLE FORMS OF N- (2,6-DIMETIL-4-MORFOLIN-4-IL-FENIL) -3,3-DIMETIL-BUTIRAMIDA

Info

Publication number
CO6460741A2
CO6460741A2 CO11153611A CO11153611A CO6460741A2 CO 6460741 A2 CO6460741 A2 CO 6460741A2 CO 11153611 A CO11153611 A CO 11153611A CO 11153611 A CO11153611 A CO 11153611A CO 6460741 A2 CO6460741 A2 CO 6460741A2
Authority
CO
Colombia
Prior art keywords
dimetil
butiramida
morfolin
fenil
stable forms
Prior art date
Application number
CO11153611A
Other languages
Spanish (es)
Inventor
Svend Treppendahl
Karin Liltorp
De Diego Heidi Lopez
Original Assignee
H Lundbeck & Co As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42237259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6460741(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck & Co As filed Critical H Lundbeck & Co As
Publication of CO6460741A2 publication Critical patent/CO6460741A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a formas cristalinas particulares de N-(2,6-dimetil-4-morfolin-4-il-fenil)-3,3-dimetil-butiramida con propiedades mejoradas y un método para tratar una enfermedad seleccionada de trastornos convulsivos, esquizofrenia, trastornos depresivos y trastornos de espectro bipolar.The present invention relates to particular crystalline forms of N- (2,6-dimethyl-4-morpholin-4-yl-phenyl) -3,3-dimethyl-butyramide with improved properties and a method of treating a disease selected from disorders seizures, schizophrenia, depressive disorders and bipolar spectrum disorders.

CO11153611A 2009-05-11 2011-11-11 STABLE FORMS OF N- (2,6-DIMETIL-4-MORFOLIN-4-IL-FENIL) -3,3-DIMETIL-BUTIRAMIDA CO6460741A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200900597 2009-05-11

Publications (1)

Publication Number Publication Date
CO6460741A2 true CO6460741A2 (en) 2012-06-15

Family

ID=42237259

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11153611A CO6460741A2 (en) 2009-05-11 2011-11-11 STABLE FORMS OF N- (2,6-DIMETIL-4-MORFOLIN-4-IL-FENIL) -3,3-DIMETIL-BUTIRAMIDA

Country Status (23)

Country Link
EP (1) EP2430008A2 (en)
JP (1) JP2012526152A (en)
KR (1) KR20120022934A (en)
CN (1) CN102459208A (en)
AR (1) AR076556A1 (en)
AU (1) AU2010246724B2 (en)
BR (1) BRPI1013930A2 (en)
CA (1) CA2761383A1 (en)
CL (1) CL2011002814A1 (en)
CO (1) CO6460741A2 (en)
CR (1) CR20110590A (en)
DO (1) DOP2011000351A (en)
EA (1) EA201171381A1 (en)
GE (1) GEP20146006B (en)
IL (1) IL216148A0 (en)
MA (1) MA33351B1 (en)
MX (1) MX2011011885A (en)
NZ (1) NZ596738A (en)
SG (1) SG175968A1 (en)
TN (1) TN2011000557A1 (en)
TW (1) TW201041857A (en)
WO (1) WO2010130260A2 (en)
ZA (1) ZA201108112B (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI349666B (en) * 2004-03-12 2011-10-01 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivatives
CA2661462C (en) * 2006-08-23 2015-09-29 Valeant Pharmaceuticals International Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
MX2010001171A (en) * 2007-08-01 2010-03-01 Lundbeck & Co As H Use of kncq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted.

Also Published As

Publication number Publication date
CR20110590A (en) 2012-02-22
MX2011011885A (en) 2011-12-06
TW201041857A (en) 2010-12-01
ZA201108112B (en) 2013-01-30
AU2010246724A1 (en) 2011-12-08
EA201171381A1 (en) 2012-05-30
CN102459208A (en) 2012-05-16
NZ596738A (en) 2013-04-26
WO2010130260A3 (en) 2011-06-16
BRPI1013930A2 (en) 2019-09-24
EP2430008A2 (en) 2012-03-21
CL2011002814A1 (en) 2012-04-13
AU2010246724B2 (en) 2013-03-21
JP2012526152A (en) 2012-10-25
SG175968A1 (en) 2011-12-29
AR076556A1 (en) 2011-06-22
WO2010130260A9 (en) 2012-10-18
TN2011000557A1 (en) 2013-05-24
IL216148A0 (en) 2012-01-31
CA2761383A1 (en) 2010-11-18
MA33351B1 (en) 2012-06-01
GEP20146006B (en) 2014-01-10
KR20120022934A (en) 2012-03-12
WO2010130260A2 (en) 2010-11-18
DOP2011000351A (en) 2012-01-31

Similar Documents

Publication Publication Date Title
BR112022003505A2 (en) Compositions and methods for treating repetitive DNA-associated disorders
AR061311A1 (en) PROCESSES TO PREPARE CINACALCET CHLORHYDRATE AND POLYMORPHIC FORMS OF THE SAME
EA201270012A1 (en) SUBLINGUAL APOMORFIN
UY34545A (en) NOVEDOSE DIHYDROPIRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS OF THE SAME FOR THE TREATMENT OF INFLAMMATORY DISORDERS.
CR20130490A (en) REPLACED PYRIMIDINES OF DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE, COMPOSITIONS OF THE SAME AND TREATMENT METHODS OF THE SAME
BR112014017021A2 (en) irak inhibitors and uses thereof
EA201290677A1 (en) CONNECTIONS OF REVERSE AMIDA AS PROTIN-DEACETYLASE INHIBITORS AND METHODS
EA201101686A1 (en) NEW COMPOSITIONS FOR THE TREATMENT OF CMT AND RELATED DISORDERS
MA32811B1 (en) NEW COMPOUNDS
BR112012000735A2 (en) "compound methods, kits and sets"
BR112013030554A2 (en) crystalline form of cyclosporin a, methods of preparation and methods for its use
EA201170356A1 (en) POLYMORPHIC AND AMORPHOUS FORMS OF LACOSAMIDE AND AMORPHOUS COMPOSITIONS
EA201500403A1 (en) COMPOUNDS ACTIVATING TELOMERASE AND METHODS OF THEIR APPLICATION
BRPI1010128A2 (en) "Process for the manufacture of 2,3,3,3 - tetrafluropropene"
EA202091731A1 (en) AUTOTAXIN INHIBITORS AND THEIR APPLICATIONS
CR8341A (en) A COMPOSITION AND TREATMENT METHOD FOR UROGENITAL CONDITIONS
CL2012002540A1 (en) Agomelatine Hydrochloride Hydrate; crystalline form; Preparation method; pharmaceutical composition; and its use for the treatment of sleep disorders, stress, anxiety, major depression, cardiovascular diseases, among others.
CO6660435A2 (en) A crystalline form of (r) -7- chloro-n- (quinuclidin -3-yl) benzo [b] thiophene-2-carboxamide hydrochloride monohydrate
EA200802072A1 (en) LIKOPIN FOR THE TREATMENT OF INFRINGEMENT OF SUBSTANCES
CR20110630A (en) CARBOXAMIDE COMPOUNDS AND ITS USE AS CALPAIN INHIBITORS
EA201290558A1 (en) AGONISTS MGLU2
CL2012001031A1 (en) 2-Oxo-1-pyrrolidinyl-imidazothiadiazole derived compounds; pharmaceutical composition comprising them; useful for the treatment of epilepsy, neurological disorders, among others.
CR20130106A (en) NEW TRPV3 MODULATORS
IT1398378B1 (en) CYTICOLINE FOR THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION.
DK2054363T3 (en) ASYMMETRIC HYDROGENATION OF 1,1,1-TRIFLUORACETONE

Legal Events

Date Code Title Description
FC Application refused